[LOGO]
                                   ORAGENICS


Contact:
Mento A."Chuck" Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

                                                           FOR IMMEDIATE RELEASE

    Oragenics Appoints Eric Chojnicki as Vice President, Product Development

ALACHUA,  FL (February 2, 2004) - Oragenics,  Inc. (OTC: OGEN;  TSX-V:ORA.U),  a
publicly held biotechnology  development company,  today announced the hiring of
Eric Chojnicki, Ph.D., MBA as vice president, product development. Dr. Chojnicki
joins the company from Acorda Therapeutics,  where he had been director, product
development since 2001.

"Eric Chojnicki comes to Oragenics with a strong  background in both science and
business garnered over 12 years at both large  pharmaceutical  and biotechnology
companies," said Mento A. "Chuck" Soponis, president and chief executive officer
of Oragenics. "His skills and experience will serve Oragenics well as we advance
clinical development and seek  commercialization  partners for our lead products
and further  investigate  earlier-stage  opportunities  where  Oragenics can add
value. We are very pleased to welcome Eric to the Oragenics team."

Since 1991, Dr.  Chojnicki has held  positions  relating to research and product
development,   as  well  as  business  development  at  such  companies  as  the
Bristol-Myers Squibb Company,  Amgen, Inc., and Athena Neurosciences,  Inc. (now
Elan  Corporation).  He received  his MBA in  pharmaceutical/chemistry  industry
management  from  Fairleigh  Dickinson  University and his Ph.D. in genetics and
developmental   biology  from  West  Virginia  University.   He  also  conducted
post-doctoral   research  studies  at  Vanderbilt  Medical  School  and  Cornell
University.

Oragenics,  Inc. is an emerging biotechnology company focused on the development
of  innovative  products  and  technologies  for  improving  human  health.  The
company's  lead product is a novel oral rinse for the prevention of tooth decay,
which is  anticipated  to enter  clinical  trials in 2004.  The  company is also
developing a novel antibiotic with broad-spectrum activity against gram-positive
bacteria and probiotic product aimed at maintaining oral health.  The company is
headquartered in Alachua, Florida. For more information about Oragenics,  please
consult the company's website at www.oragenics.com.

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995: This release includes forward-looking  statements which reflect Oragenics'
current  views with respect to future events and  financial  performance.  These
forward-looking statements are based on management's beliefs and assumptions and
information currently available.  The words "believe",  "expect",  "anticipate",
"intend",  "estimate",  "project"  and similar  expressions  which do not relate
solely to historical  matters  identify  forward-looking  statements.  Investors
should be cautious in relying on  forward-looking  statements  because  they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual  results  to  differ   materially   from  those  expressed  in  any  such
forward-looking  statements.  These factors include,  but are not limited to (1)
the  ability to  successfully  complete  development  and  commercialization  of
Oragenics'  Replacement Therapy for prevention of tooth decay, novel antibiotic,
and  probiotic  product for oral health;  (2) the ability to obtain  substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;  and (4) other  factors  detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking  statements. The TSX Venture Exchange has not reviewed
and does not accept  responsibility  for the  adequacy  or accuracy of this news
release.

                                      # # #